News. The latest from Sarborg.
Press releases, platform milestones, partnerships and patents.
- Press Release12 May 2026
Sarborg Curates Veterinary Disease Database to Expand AI Signature Intelligence Platform into Animal Health
Sarborg today announced the curation of the Sarborg Veterinary Disease Database, a proprietary collection of veterinary disease signatures that significantly expands the Company's AI Signature Agent platform into the global animal health market.
Download PDF → - Press Release7 May 2026
Sarborg Leverages Signature AI Agents to File Substance of Matter Patent in Cystic Fibrosis Market
Sarborg leverages its Signature AI Agents to file a substance-of-matter patent application in the cystic fibrosis market.
Download PDF → - Press Release28 Apr 2026
Sarborg Acquires Portfolio of Next-Generation Patented Cannabinoid Solid-Form Assets
Sarborg today announced that it has completed the acquisition of a portfolio of solid-form cannabinoid assets from Manoira Corporation.
Download PDF → - Press Release7 Apr 2026
Sarborg Publishes PRISM: A Cross-Species Connectivity Mapping Framework for Translational Agriculture
Sarborg publishes PRISM, a cross-species connectivity mapping framework for translational agriculture.
Download PDF → - Press Release7 Apr 2026
PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture
Sarborg publishes PRISM, a cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture.
Download PDF → - Press Release12 Mar 2026
Sarborg Curates Rare Disease Signature Database to Expand AI Signature Intelligence Platform
Sarborg today announced the curation of a rare disease signature database containing approximately 1,700 disease signatures, further expanding the datasets available to its proprietary AI Signature Agent platform.
Download PDF → - Press Release5 Mar 2026
Sarborg Files U.S. Provisional Patent Application for its AI Signature Agent
Sarborg today announced that it has filed a provisional patent application with the USPTO in relation to its proprietary AI Signature Agent.
Download PDF → - Press Release24 Feb 2026
Sarborg Expands AI Agentic Signature Platform Beyond Pharmaceuticals into Bacteria and Agrochemicals
Expansion of its proprietary AI Signature Agent platform into additional high-impact sectors, including bacteria and agrochemicals, following the successful deployment of its Pharmaceutical Signature Agent.
Download PDF → - Press Release15 Dec 2025
Sarborg Develops and Curates “Sarborg 1,600” Gold Standard Disease Signature Database
Curation and development of its proprietary “Sarborg 1,600,” a gold standard database of approximately 1,600 structured disease signatures designed specifically for integration with the Company's AI Signature Agent.
Download PDF → - Press Release8 Dec 2025
Sarborg Signature Agent Completion
Sarborg announces the completion of development of its proprietary AI Signature Agent, initially focused on matching drug and disease signatures within the pharmaceutical sector.
Download PDF → - Press Release9 Sept 2025
Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach
Funding supports next-generation AI agent development and proprietary intellectual property, focused initially on pharmaceutical drug repurposing.
Download PDF → - Press Release27 Aug 2025
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach
Conduit Pharmaceuticals partners with Sarborg Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring.